Spyre Therapeutics Inc. (SYRE) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Spyre Therapeutics Inc. (SYRE) has a cash flow conversion efficiency ratio of -0.086x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-57.54 Million) by net assets ($670.81 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See debt-free asset ratio of Spyre Therapeutics Inc. to measure how much of total assets are equity-financed.
Spyre Therapeutics Inc. - Cash Flow Conversion Efficiency Trend (2014–2025)
This chart illustrates how Spyre Therapeutics Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Check SYRE capex plus investments ratio to assess the company's total reinvestment commitment from operating cash flow.
Spyre Therapeutics Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Spyre Therapeutics Inc. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
GUOTAI JUNAN SEC. H YC1
F:153A
|
0.155x |
|
D-Wave Quantum Inc.
NYSE:QBTS
|
-0.040x |
|
Unicaja Banco SA
MC:UNI
|
0.006x |
|
Avanza Bank Holding AB (publ)
ST:AZA
|
1.029x |
|
KION GROUP AG ADRS/1/4
F:KGX1
|
0.037x |
|
The Hanover Insurance Group Inc
NYSE:THG
|
0.033x |
|
Ringkjoebing Landbobank A/S
CO:RILBA
|
0.002x |
|
Dosilicon Co Ltd
SHG:688110
|
-0.029x |
Annual Cash Flow Conversion Efficiency for Spyre Therapeutics Inc. (2014–2025)
The table below shows the annual cash flow conversion efficiency of Spyre Therapeutics Inc. from 2014 to 2025. For the full company profile with market capitalisation and key ratios, see SYRE stock market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $715.24 Million | $-169.25 Million | -0.237x | +22.16% |
| 2024-12-31 | $517.80 Million | $-157.41 Million | -0.304x | +44.01% |
| 2023-12-31 | $184.02 Million | $-99.91 Million | -0.543x | +65.92% |
| 2022-12-31 | $50.30 Million | $-80.14 Million | -1.593x | -148.96% |
| 2021-12-31 | $83.94 Million | $-53.72 Million | -0.640x | -18.09% |
| 2020-12-31 | $139.83 Million | $-75.78 Million | -0.542x | +50.44% |
| 2019-12-31 | $60.08 Million | $-65.69 Million | -1.093x | -129.01% |
| 2018-12-31 | $67.43 Million | $-32.19 Million | -0.477x | +2.36% |
| 2017-12-31 | $50.34 Million | $-24.61 Million | -0.489x | -63.43% |
| 2016-12-31 | $62.97 Million | $-18.84 Million | -0.299x | +1.63% |
| 2015-12-31 | $36.10 Million | $-10.98 Million | -0.304x | +92.24% |
| 2014-12-31 | $1.87 Million | $-7.33 Million | -3.918x | -- |
About Spyre Therapeutics Inc.
Spyre Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD) and rheumatic diseases. The company develops SPY001, a humanized monoclonal immunoglobulin G1 antibody that is in phase-2 clinical stage designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative … Read more